These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28726123)

  • 1. Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?
    Broomfield A; Fletcher J; Hensman P; Wright R; Prunty H; Pavaine J; Jones SA
    JIMD Rep; 2018; 39():55-62. PubMed ID: 28726123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
    Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
    Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement.
    Paoletti M; Pichiecchio A; Colafati GS; Conte G; Deodato F; Gasperini S; Menni F; Furlan F; Rubert L; Triulzi FM; Cinnante C
    Front Neurol; 2020; 11():569153. PubMed ID: 33329311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor outcomes in patients with infantile and juvenile Pompe disease: Lessons from neurophysiological findings.
    Brassier A; Pichard S; Schiff M; Bouchereau J; Bérat CM; Caillaud C; Pion A; Khraiche D; Fauroux B; Oualha M; Barnerias C; Desguerre I; Hully M; Maquet M; Deladrière E; de Lonlay P; Gitiaux C
    Mol Genet Metab; 2023 Aug; 139(4):107650. PubMed ID: 37454519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Timely Needs for Infantile Onset Pompe Disease Newborn Screening-Practice in Taiwan.
    Chiang SC; Chien YH; Chang KL; Lee NC; Hwu WL
    Int J Neonatal Screen; 2020 Jun; 6(2):30. PubMed ID: 33073026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells.
    Yoshida T; Jonouchi T; Osafune K; Takita J; Sakurai H
    Front Cell Dev Biol; 2019; 7():316. PubMed ID: 31850350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.
    Al-Hassnan ZN; Khalifa OA; Bubshait DK; Tulbah S; Alkorashy M; Alzaidan H; Alowain M; Rahbeeni Z; Al-Sayed M
    Mol Genet Metab Rep; 2018 Jun; 15():50-54. PubMed ID: 30023291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome and unmet needs in infantile-onset Pompe disease.
    Hahn A; Schänzer A
    Ann Transl Med; 2019 Jul; 7(13):283. PubMed ID: 31392195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years.
    Schänzer A; Görlach J; Claudi K; Hahn A
    Neuromuscul Disord; 2019 Jun; 29(6):477-482. PubMed ID: 31101460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.
    McIntosh PT; Hobson-Webb LD; Kazi ZB; Prater SN; Banugaria SG; Austin S; Wang R; Enterline DS; Frush DP; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):85-91. PubMed ID: 29050825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Providing the conduit for treatment: The impact of vascular access and vein preservation in a 5-year-old child with prenatally diagnosed CRIM-negative Infantile Pompe disease.
    Ostroff M; Gupta P; Garcia D
    J Vasc Access; 2021 Mar; ():1129729821999486. PubMed ID: 33673749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
    Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
    Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
    Desai AK; Kazi ZB; Bali DS; Kishnani PS
    Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.